The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
Philip S HelliwellJessica A WalshSoumya D ChakravartySteven PetersonKim Hung LoLilianne KimNan LiElizabeth C HsiaEric K H ChanArthur KavanaughM Elaine HusniPublished in: Clinical rheumatology (2021)
IV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability. Key Points • In patients with active psoriatic arthritis (PsA), intravenous (IV) golimumab improved health-related quality of life (HRQoL) and productivity as early as 8 weeks and maintained improvement through 1 year • Improvements in HRQoL and productivity outcomes in patients with PsA treated with IV golimumab were associated with improvements in disease activity and patient functional capability outcomes • IV golimumab is an effective treatment option for PsA that can mitigate the negative effects of the disease on HRQoL and productivity.
Keyphrases
- ankylosing spondylitis
- disease activity
- climate change
- prostate cancer
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- radical prostatectomy
- ulcerative colitis
- juvenile idiopathic arthritis
- high dose
- case report
- clinical trial
- metabolic syndrome
- low dose
- type diabetes
- adipose tissue
- phase iii
- gestational age
- smoking cessation
- double blind